About
Monoclonal Antibodies, ADCs, Bispecifics
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyChina
Clinical Trials (64)
View allTotal Trials
64
As Lead Sponsor
61
As Collaborator
3
Total Enrollment
7,902
By Phase
PHASE1/PHASE2: 12PHASE2: 25PHASE3: 9PHASE1: 16NA: 2
By Status
COMPLETED: 24NOT_YET_RECRUITING: 19RECRUITING: 12UNKNOWN: 6ACTIVE_NOT_RECRUITING: 3
Clinical Trials Pipeline64 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT07175493Lead Sponsor
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
PHASE1/PHASE2Not yet recruiting
158 participants
Started: Oct 31, 2025 · Completed: Oct 31, 2028
NCT06830395Lead Sponsor
Study of CM313 in Subject With IgA Nephropathy
PHASE2Not yet recruiting
106 participants
Started: Sep 30, 2025 · Completed: Aug 31, 2028
NCT07106372Lead Sponsor
A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
PHASE3Not yet recruiting
240 participants
Started: Sep 30, 2025 · Completed: Jun 30, 2027
NCT07175506Lead Sponsor
Study of CM559 in Healthy Subjects
PHASE1Recruiting
40 participants
Started: Sep 30, 2025 · Completed: Jun 30, 2026
NCT07181239Lead Sponsor
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
PHASE3Not yet recruiting
280 participants
Started: Sep 30, 2025 · Completed: Apr 30, 2030
Locations (1)
Headquarters
Chengdu, China
Map
Loading map...